Serono in talks with top pharma companies about potential takeover

Share this article:
Serono has held talks with Novartis, GlaxoSmithKline, Sanofi-Aventis and Pfizer in recent weeks about a potential $15 billion takeover of the company, The Wall Street Journal reported today.
Serono, based in Geneva, Switzerland, is the world's third largest biotech company by sales.
In a statement, the company said that it has hired investment bank Goldman Sachs Group "to explore various strategic alternatives for the company," adding that "there can be no assurances that any transaction will be consummated."
Any buyer would most likely be interested in Serono's multiple sclerosis drug Rebif, which had sales of $1 billion in 2004. The company also sells drugs to treat infertility and is attempting to develop 30 new medicines for cancer, inflammatory diseases and other therapeutic areas.
Share this article:

Next Article in News

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches

GSK relaunches

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.